Power Shortage: Clinical Trials Testing the “Homocysteine Hypothesis” against a Background of Folic Acid–Fortified Cereal Grain Flour
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Large randomized, controlled trials of total homocysteine-lowering therapy for the potential reduction of cardiovascular disease outcomes are ongoing in the United States and Canada. These trials are the Vitamin Intervention for Stroke Prevention (VISP) trial, the Women's Antioxidant Cardiovascular Disease Study (WACS), and the Heart Outcomes Prevention Evaluation (HOPE-2). However, the dramatic effect of policies mandating fortification of cereal grain flour products with folic acid may reduce the statistical power of these trials. All three trials assume that the active treatment groups will achieve the same mean effects of total homocysteine-lowering therapy as those reported in the absence of folic acid-fortified cereal grain flour. This paper examines this assumption using data from studies of total homocysteine-lowering therapy in U.S. and Canadian patients with cardiovascular disease who were exposed to products made with folic acid-fortified cereal grain flour. These data showed that the VISP trial, HOPE-2, and WACS will probably achieve only approximately 20% to 25% of the projected treatment effects of mean total homocysteine-lowering therapy (1.0 to 1.5 micromol/L vs. 4.0 to 6.0 micromol/L). As a result, all three trials will be substantially underpowered to test the specific hypotheses of total homocysteine-lowering therapy identified a priori. In contrast, renal transplant recipients have a persistent excess prevalence of hyperhomocysteinemia in the era of fortification but remain very responsive to supraphysiologic doses of folic acid-based supplementation (mean reduction in total homocysteine level, 5.0 to 6.0 micromol/L). Therefore, unlike other populations with normal renal function that are at high risk for cardiovascular disease but are profoundly affected by fortification efforts, renal transplant recipients continue to merit serious consideration for a controlled trial of the "homocysteine hypothesis."
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mann, J. F. E., Gerstein, H. C., Pogue, J., Bosch, J., Yusuf, S., & for the HOPE Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00007 · Cited by 1,372
Cited by
Optimal Diets for Prevention of Coronary Heart Disease
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.288.20.2569 · Cited by 1,503
“Ongoing clinical trials should provide more definitive data on the role of folic acid supplementation in CHD prevention, but the interpretation of the findings from trials conducted in the United States could be complicated by the fortification of flour with folic acid.(94)”
BackgroundFacts and recommendations about total homocysteine determinations: an expert opinion
Refsum, H., Smith, A. D., Ueland, P. M., Nexo, E., Clarke, R., McPartlin, J., Johnston, C., Engbaek, F., Schneede, J., McPartlin, C., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.021634 · Cited by 1,056
Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
Hackam, D. G., & Anand, S. S. (2003) · JAMA · doi:10.1001/jama.290.7.932 · Cited by 550
Albert, C. M., Cook, N. R., Gaziano, J. M., Zaharris, E., MacFadyen, J., Danielson, E., Buring, J. E., & Manson, J. E. (2008) · JAMA · doi:10.1001/jama.299.17.2027 · Cited by 511
Bazzano, L. A., Reynolds, K., Holder, K. N., & He, J. (2006) · JAMA · doi:10.1001/jama.296.22.2720 · Cited by 426
Metadata
- Authors
- Bostom, A. G., Selhub, J., Jacques, P. F., & Rosenberg, I. H.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2001-07-17
- Volume
- 135
- Issue
- 2
- Pages
- 133-137
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1971092152
- Cited by
- 101
- References
- 1
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Power Shortage: Clinical Trials Testing the “Homocysteine Hypothesis” against a Background of Folic Acid–Fortified Cereal Grain Flour. https://app.cochat.ai/papers/10.7326/0003-4819-135-2-200107170-00014
- The paper
- Bostom, A. G., Selhub, J., Jacques, P. F., & Rosenberg, I. H. (2001). Power Shortage: Clinical Trials Testing the “Homocysteine Hypothesis” against a Background of Folic Acid–Fortified Cereal Grain Flour. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-135-2-200107170-00014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.